GILEAD SCIENCES INC (NASDAQ: GILD)

GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Kemas kini terakhir: 06 Mar, 3:50AM

145.14

-3.08 (-2.08%)

Tambah ke senarai pantauan

Penutupan Terdahulu	148.22
Buka	146.51
Jumlah Dagangan	6,915,056
Purata Dagangan (3B)	7,458,168
Modal Pasaran	180,179,779,584

Harga / Pendapatan (P/E TTM)	21.41
Harga / Pendapatan (P/E Ke hadapan)	16.69
Harga / Jualan (P/S)	6.22
Harga / Buku (P/B)	7.98

Julat 52 Minggu	93.37 (-35%) — 157.29 (8%)
Tarikh Pendapatan	23 Apr 2026
Hasil Dividen (DY TTM)	1.63%

Arah Aliran Pasaran

		Jangka Pendek	Jangka Sederhana
Industri	Drug Manufacturers - General (US)	Menaik	Bercampur
	Drug Manufacturers - General (Global)	Menaik	Bercampur
Stok	Gilead Sciences, Inc.	Menaik	Menaik

AISkor Stockmoo

1.2

Konsensus Penganalisis	1.5
Aktiviti Orang Dalam	3.0
Volatiliti Harga	-0.5
Purata Bergerak Teknikal	2.5
Osilator Teknikal	-0.5
Purata	1.20

Saham Serupa

Stok	Modal Pasaran	DY	P/E (TTM)	P/B
GILD	180 B	1.63%	21.41	7.98
AMGN	198 B	2.63%	25.83	23.51
AZN	301 B	0.27%	29.75	6.21
SNY	109 B	4.92%	19.15	1.28
BIIB	26 B	-	16.16	1.53
GRFS	8 B	1.91%	14.00	0.910

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sektor	Healthcare
Industri	Drug Manufacturers - General
Gaya Pelaburan	Large Value
% Dimiliki oleh Orang Dalam	0.10%
% Dimiliki oleh Institusi	89.79%

Julat 52 Minggu	93.37 (-35%) — 157.29 (8%)
Julat Harga Sasaran	118.00 (-18%) — 180.00 (24%)
Tinggi	180.00 (Jefferies, 24.02%)	Beli
Median	155.00 (6.79%)
Rendah	118.00 (RBC Capital, -18.70%)	Pegang
Purata	157.55 (8.55%)
Jumlah	9 Beli, 2 Pegang
Harga Purata @ Panggilan	148.12

Syarikat	Tarikh	Harga Sasaran	Panggilan	Harga @ Panggilan
Jefferies	10 Mar 2026	180.00 (24.02%)	Beli	148.56
Needham	23 Feb 2026	170.00 (17.13%)	Beli	149.83
Needham	11 Feb 2026	170.00 (17.13%)	Beli	155.80
Barclays	20 Feb 2026	155.00 (6.79%)	Pegang	151.40
Cantor Fitzgerald	11 Feb 2026	155.00 (6.79%)	Beli	155.80
RBC Capital	11 Feb 2026	118.00 (-18.70%)	Pegang	155.80
Scotiabank	11 Feb 2026	177.00 (21.95%)	Beli	155.80
Truist Securities	11 Feb 2026	152.00 (4.73%)	Beli	155.80
Truist Securities	27 Jan 2026	145.00 (-0.10%)	Beli	140.97
Wells Fargo	11 Feb 2026	165.00 (13.68%)	Beli	155.80
Citigroup	27 Jan 2026	156.00 (7.48%)	Beli	140.97
Citigroup	07 Jan 2026	140.00 (-3.54%)	Beli	124.35
UBS	26 Jan 2026	155.00 (6.79%)	Beli	137.78
UBS	07 Jan 2026	145.00 (-0.10%)	Beli	124.35
Morgan Stanley	13 Jan 2026	150.00 (3.35%)	Beli	121.76
Papar semua

Tiada data dalam julat masa ini.

Tarikh	Jenis	Butiran
06 Feb 2026	Pengumuman	FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
27 Jan 2026	Pengumuman	Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
21 Jan 2026	Pengumuman	New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
06 Jan 2026	Pengumuman	OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate
22 Dec 2025	Pengumuman	Gilead Sciences to Present at Upcoming Investor Conference
22 Dec 2025	Pengumuman	Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
19 Dec 2025	Pengumuman	Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
19 Dec 2025	CNBC	Nine of the largest pharma companies ink deals with Trump to lower drug prices
18 Dec 2025	Pengumuman	Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
15 Dec 2025	Pengumuman	Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

Hasil Dividen (DY TTM)	1.63%
Purata Hasil Dividen 5T	3.38%
Nisbah Pembayaran	65.13%
Jangkaan Pembayaran Dividen Seterusnya	Mar 2026

Tarikh EX	Tarikh Pengumuman	Tarikh Pembayaran	Perincian
15 Dec 2025	28 Oct 2025	30 Dec 2025	0.79 Tunai
15 Sep 2025	29 Jul 2025	29 Sep 2025	0.79 Tunai
13 Jun 2025	22 Apr 2025	27 Jun 2025	0.79 Tunai
14 Mar 2025	05 Feb 2025	28 Mar 2025	0.79 Tunai
13 Dec 2024	30 Oct 2024	30 Dec 2024	0.77 Tunai
13 Sep 2024	30 Jul 2024	27 Sep 2024	0.77 Tunai
14 Jun 2024	23 Apr 2024	27 Jun 2024	0.77 Tunai
14 Mar 2024	01 Feb 2024	28 Mar 2024	0.77 Tunai
14 Dec 2023	01 Nov 2023	28 Dec 2023	0.75 Tunai
14 Sep 2023	25 Jul 2023	28 Sep 2023	0.75 Tunai
14 Jun 2023	25 Apr 2023	29 Jun 2023	0.75 Tunai
14 Mar 2023	25 Jan 2023	30 Mar 2023	0.75 Tunai
14 Dec 2022	25 Oct 2022	29 Dec 2022	0.73 Tunai
14 Sep 2022	25 Jul 2022	29 Sep 2022	0.73 Tunai
14 Jun 2022	27 Apr 2022	29 Jun 2022	0.73 Tunai
14 Mar 2022	28 Jan 2022	30 Mar 2022	0.73 Tunai
14 Dec 2021	26 Oct 2021	30 Dec 2021	0.71 Tunai
14 Sep 2021	26 Jul 2021	29 Sep 2021	0.71 Tunai
14 Jun 2021	27 Apr 2021	29 Jun 2021	0.71 Tunai
12 Mar 2021	02 Feb 2021	30 Mar 2021	0.71 Tunai
14 Dec 2020	26 Oct 2020	30 Dec 2020	0.68 Tunai
14 Sep 2020	29 Jul 2020	29 Sep 2020	0.68 Tunai
11 Jun 2020	29 Apr 2020	29 Jun 2020	0.68 Tunai
12 Mar 2020	03 Feb 2020	30 Mar 2020	0.68 Tunai
12 Dec 2019	23 Oct 2019	30 Dec 2019	0.63 Tunai
12 Sep 2019	29 Jul 2019	27 Sep 2019	0.63 Tunai
13 Jun 2019	01 May 2019	27 Jun 2019	0.63 Tunai
14 Mar 2019	01 Feb 2019	28 Mar 2019	0.63 Tunai
13 Dec 2018	24 Oct 2018	28 Dec 2018	0.57 Tunai
13 Sep 2018	24 Jul 2018	27 Sep 2018	0.57 Tunai
14 Jun 2018	30 Apr 2018	28 Jun 2018	0.57 Tunai
15 Mar 2018	05 Feb 2018	29 Mar 2018	0.57 Tunai
14 Dec 2017	25 Oct 2017	28 Dec 2017	0.52 Tunai
14 Sep 2017	25 Jul 2017	28 Sep 2017	0.52 Tunai
14 Jun 2017	01 May 2017	29 Jun 2017	0.52 Tunai
14 Mar 2017	06 Feb 2017	30 Mar 2017	0.52 Tunai
13 Dec 2016	31 Oct 2016	29 Dec 2016	0.47 Tunai
14 Sep 2016	22 Jul 2016	29 Sep 2016	0.47 Tunai
14 Jun 2016	27 Apr 2016	29 Jun 2016	0.47 Tunai
14 Mar 2016	02 Feb 2016	30 Mar 2016	0.43 Tunai
14 Dec 2015	26 Oct 2015	30 Dec 2015	0.43 Tunai
14 Sep 2015	23 Jul 2015	29 Sep 2015	0.43 Tunai
12 Jun 2015	24 Apr 2015	29 Jun 2015	0.43 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun	Dividen Tahunan ($)	Kekerapan/Tahun	Hasil %
2025	3.16	4	2.58
2024	3.08	4	3.33
2023	3.00	4	3.70
2022	2.92	4	3.40
2021	2.84	4	3.91
2020	2.72	4	4.67
2019	2.52	4	3.88
2018	2.28	4	3.65
2017	2.08	4	2.90
2016	1.84	4	2.57
2015	1.29	3	1.28
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

Log masuk untuk menambahkan ke senarai pantauan

AI Templat

Peringatan harga anda

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Log masuk untuk menambahkan ke senarai pantauan

Keuntungan Nyata	-
Keuntungan Tidak Nyata	-
Dividen Diterima 2026	-
Jumlah Untung	-
Pulangan Purata	-
Kuantiti (Beli)	-
Purata Harga (Beli)	-
Kuantiti (Jual)	-
Purata Harga (Jual)	-

Log masuk untuk menambahkan ke senarai pantauan

Tiada saham yang memenuhi kriteria anda

Margin Keuntungan	20.76%
Margin Operasi (TTM)	38.49%
EPS Cair (TTM)	4.76
Pertumbuhan Hasil Suku Tahunan (YOY)	-0.30%
Pertumbuhan Pendapatan Suku Tahunan (YOY)	24.80%

Jumlah Hutang/Ekuiti (D/E MRQ)	130.79%
Nisbah Semasa (MRQ)	1.37
Aliran Tunai Operasi (OCF TTM)	10.37 B
Aliran Tunai Bebas Leveraj (LFCF TTM)	9.99 B

Pulangan Atas Aset (ROA TTM)	12.14%
Pulangan Atas Ekuiti (ROE TTM)	32.65%

Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)